D018696Chemicals & DrugsPhysiologyD27.505.696.706.548D27.505.954.427.5751042120.835793Neuroprotective AgentsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonSymptom Research CAOMD AndersonCOBI JACOBA JOHANNAHEIJNENCOBI JACOBA JOHANNA HEIJNEN9871HEIJNEN, COBI JACOBA JOHANNAProfessorTIANHONGPANTIANHONG PAN9887PAN, TIANHONGInstructor74Professor54InstructorOrthopaedic Oncologytrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor3.587530.00877514104research area of0.9614780.03965187subject area forPharmacological & Pharmaceutical SciencesDepartment of NeurologyNeurologyBaylor College of MedicineUniversity of Houston College of PharmacyJOSEPHJANKOVICJOSEPH JANKOVIC0.000000000000000.000000000000002398JANKOVIC, JOSEPHProfessorKARIMALKADHIKARIM A. ALKADHI29.72602660000000-95.348164100000004613ALKADHI, KARIMProfessorDIANACHOWDIANA S-L. CHOW29.70508570000000-95.401808700000004619CHOW, DIANAProfessor35120261Wirianto M, Wang CY, Kim E, Koike N, Gomez-Gutierrez R, Nohara K, Escobedo G, Choi JM, Han C, Yagita K, Jung SY, Soto C, Lee HK, Morales R, Yoo SH, Chen ZFASEB journal : official publication of the Federation of American Societies for Experimental BiologyThe clock modulator Nobiletin mitigates astrogliosis-associated neuroinflammation and disease hallmarks in an Alzheimer's disease model. FASEB J. 2022 03; 36(3):e22186.FASEB J2022-03-01T00:00:002022The clock modulator Nobiletin mitigates astrogliosis-associated neuroinflammation and disease hallmarks in an Alzheimer's disease model.35830641Wu YW, Comstock BA, Gonzalez FF, Mayock DE, Goodman AM, Maitre NL, Chang T, Van Meurs KP, Lampland AL, Bendel-Stenzel E, Mathur AM, Wu TW, Riley D, Mietzsch U, Chalak L, Flibotte J, Weitkamp JH, Ahmad KA, Yanowitz TD, Baserga M, Poindexter BB, Rogers EE, Lowe JR, Kuban KCK, O'Shea TM, Wisnowski JL, McKinstry RC, Bluml S, Bonifacio S, Benninger KL, Rao R, Smyser CD, Sokol GM, Merhar S, Schreiber MD, Glass HC, Heagerty PJ, Juul SE, HEAL ConsortiumThe New England journal of medicineTrial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns. N Engl J Med. 2022 07 14; 387(2):148-159.N Engl J Med2022-07-14T00:00:002022Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.37130044Chow DS, Nguyen A, Park J, Wu L, Toups EG, Harrop JS, Guest JD, Schmitt KM, Aarabi B, Fehlings MG, Boakye M, Grossman RGJournal of neurotraumaRiluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial. J Neurotrauma. 2023 09; 40(17-18):1889-1906.J Neurotrauma2023-09-01T00:00:002023Riluzole in Spinal Cord Injury Study (RISCIS)-Pharmacokinetic (PK) Sub-Study: An Analysis of Pharmacokinetics, Pharmacodynamics, and Impact on Axonal Degradation of Riluzole in Patients With Traumatic Cervical Spinal Cord Injury Enrolled in the RISCIS Phase III Randomized Controlled Trial.37279301Fehlings MG, Moghaddamjou A, Harrop JS, Stanford R, Ball J, Aarabi B, Freeman BJC, Arnold PM, Guest JD, Kurpad SN, Schuster JM, Nassr A, Schmitt KM, Wilson JR, Brodke DS, Ahmad FU, Yee A, Ray WZ, Brooks NP, Wilson J, Chow DS, Toups EG, Kopjar BJournal of neurotraumaSafety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial. J Neurotrauma. 2023 09; 40(17-18):1878-1888.J Neurotrauma2023-07-13T00:00:002023Safety and Efficacy of Riluzole in Acute Spinal Cord Injury Study (RISCIS): A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Trial.37295854Andropoulos DBBest practice & research. Clinical anaesthesiologyNeuroprotective strategies in anesthesia-induced neurotoxicity. Best Pract Res Clin Anaesthesiol. 2023 Mar; 37(1):52-62.Best Pract Res Clin Anaesthesiol2022-12-05T00:00:002022Neuroprotective strategies in anesthesia-induced neurotoxicity.true1InstructorInstructortrue1ProfessorProfessor